Updated:
Verrica Pharmaceuticals
Verrica Pharmaceuticals, led by CEO Ted White, markets Ycanth — the first FDA-approved drug-device treatment for molluscum contagiosum in children.
Verrica Pharmaceuticals
Verrica Pharmaceuticals was founded in 2013 and is headquartered in West Chester, Pennsylvania. The company is led by President and CEO Ted White, who joined in 2017 after a career spanning Novartis, GSK, and a series of specialty pharma roles. Verrica went public in 2018, raising capital to advance a pipeline centered on skin diseases with limited treatment options. Its founding premise was straightforward: identify underserved dermatological conditions where a precise, locally delivered therapy can win a clear first-mover advantage. The company's commercial strategy currently revolves around Ycanth (VP-102), a proprietary drug-device combination that delivers a standardized formulation of cantharidin to treat molluscum contagiosum, a highly contagious viral skin infection affecting millions of children annually in the United States. Ycanth was approved by the FDA in July 2023, making it the first FDA-approved treatment for the condition. Verrica owns global rights to the product and handles U.S. commercialization directly. The company has also explored cantharidin for external genital warts and common warts, though molluscum remains the near-term revenue engine. Verrica is a single-product story with additional pipeline assets in early development, including VP-315 for basal cell carcinoma. Verrica operates as a lean commercial biotech with a team concentrated in the U.S. No international offices or large-field sales numbers are publicly available. The company executed a public offering in May 2024 to fund the ongoing Ycanth launch. While Verrica does not operate philanthropic foundations or parallel investment vehicles, it partners with pediatric dermatology networks and payers to secure formulary access — a structural gate every niche biotech must unlock. Market access for a first-in-class pediatric therapy defines the firm's near-term operational risk. Verrica's structural differentiator is its monopoly-by-approval posture in a contained, high-volume pediatric indication. Most dermatology players target atopic dermatitis or psoriasis — crowded, generic-saturated categories. Verrica's focused bet on molluscum means the company's entire valuation rests on a single commercial execution play. This concentration risk is offset by a patent estate and the 7-year orphan drug exclusivity granted to Ycanth, making the firm an unusually binary but analytically clean bet for healthcare-focused allocators (per public record, 2023).
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
West Chester
Corporate office
West Chester, PA, United States
Principals
Ted White
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Verrica Pharmaceuticals?
Verrica is not an investment firm. It is a commercial-stage biopharmaceutical company. Strategic and capital allocation decisions rest with President and CEO Ted White and are overseen by an independent board of directors. Major financial moves, including equity raises and commercial partnerships, are approved through this governance structure.
What is Verrica's only FDA-approved product, and why does it matter?
Ycanth (VP-102) is a drug-device combination delivering a precise dose of cantharidin for treating molluscum contagiosum in patients aged two and older. FDA approval in July 2023 made it the first-ever approved therapy for the condition. The approval grants 7 years of orphan drug exclusivity, creating a temporary monopoly in a market with an estimated 6 million annual U.S. patient visits.
Is Verrica subject to generic competition on Ycanth?
Near-term generic competition is unlikely. Ycanth benefits from orphan drug exclusivity and a proprietary applicator device that forms part of the intellectual property estate. Historically, compounded cantharidin has been available through specialty pharmacies, but no FDA-approved generic cantharidin product exists, and compounded versions lack the standardized dosing of the Ycanth device.
Does Verrica have any pipeline beyond molluscum?
The company has evaluated cantharidin for external genital warts, with a Phase 2 program, and holds early-stage rights to VP-315 for basal cell carcinoma. However, Ycanth for molluscum contagiosum represents the company's sole commercial-stage asset. All pipeline programs are pre-revenue and early clinical-stage at present.
How does Verrica commercialize Ycanth in the U.S.?
Verrica uses a dedicated U.S. sales force targeting pediatric dermatologists, primary care physicians, and payers. The company does not rely on a larger pharmaceutical partner for domestic commercialization. Payer coverage for Ycanth is secured through standard formulary negotiations and prior authorization processes typical for branded dermatology products.
What is Ted White's background?
Ted White joined Verrica as President and CEO in 2017. He previously served in leadership roles at Novartis and in global marketing at GSK. His career has been concentrated in specialty pharmaceuticals and dermatology, which shaped Verrica's commercial focus on niche, under-treated skin conditions rather than broad primary-care markets.
Is Verrica involved in any investment partnerships or family office structures?
No. Verrica Pharmaceuticals is a publicly traded commercial biotech firm (NASDAQ: VRCA) and does not operate as an investment vehicle, family office, or fund manager. All capital deployment is directed toward internal drug development, regulatory advancement, and commercial operations for its own pipeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: